Serum il-18 and rs187238 single nucleotide polymorphism are associated with high-density lipoprotein changes in covid-19 outpatients
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110645 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Glautemberg de Almeida Viana und 9 weiteren Autor:innen. Beteiligte Einrichtung: Program in Pharmaceutical Sciences; Faculty of Pharmacy, Dentistry and Nursing; Federal University of Ceará, Brazil. Hauptthemen laut MEDLINE: COVID-19, Interleukin-18, Lipoproteins, HDL. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
AIM: COVID-19 is an inflammatory disease and its prognosis is associated with cardiovascular risk, which can be associated with changes in lipoprotein metabolism. The single nucleotide polymorphism (SNP) rs187238 of Interleukin (IL)-18 is extensively reported in association with worsening inflammatory and cardiovascular disease (CVD). This study evaluated the association of IL-18 levels and its SNP rs187238 with lipoprotein profile changes in COVID-19 outpatients. METHODS: Observational, analytical, cross-sectional study that evaluated 250 patients with respiratory syndrome, 36% (n = 90) with COVID-19. Serum total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), triglycerides (TG), apolipoproteins A-I and B (Apo A-I and Apo B) and IL-18 levels were determined. Polymorphism genotyping was done by real-time polymerase chain reaction (qPCR). The significance level was p < 0.05. RESULTS: Patients with COVID-19 showed a reduction in TC and HDL-c, without difference in IL-18. HDL-c and LDL-c had a high frequency outside the reference values. There was a negative correlation of IL-18 with HDL-c and a positive correlation with Apo B/Apo A-I ratio. The frequencies of the C (wild) and G (polymorphic) alleles between patients with and without COVID-19 followed the Hardy-Weinberg equilibrium. However, COVID-19 was associated with reduced HDL-c and Apo A-I values in patients with the CC genotype. CONCLUSION: IL-18 levels and its SNP rs187238 were associated with decreased HDL-c and Apo A-I in COVID-19 outpatients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Program in Pharmaceutical Sciences; Faculty of Pharmacy, Dentistry and Nursing; Federal University of Ceará, Brazil.
- Department of Clinical and Toxicological Analysis; Faculty of Pharmacy, Dentistry and Nursing; Federal University of Ceará, Brazil.
- Program in Pharmaceutical Sciences; Faculty of Pharmacy, Dentistry and Nursing; Federal University of Ceará, Brazil; Department of Clinical and Toxicological Analysis; Faculty of Pharmacy, Dentistry and Nursing; Federal…
Zitieren
APA
Viana, G. A., da Costa, M. D. R., da Silva, M. E., Duque, B. R., de Siqueira, E. A., Martins, A. M. C., Alves, R. S., de Menezes, R. R. P. P. B., de Queiroz, M. G. R., & Sampaio, T. L. (2023). Serum il-18 and rs187238 single nucleotide polymorphism are associated with high-density lipoprotein changes in covid-19 outpatients. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110645
Vancouver
Viana GA, da Costa MDR, da Silva ME, Duque BR, de Siqueira EA, Martins AMC, et al. Serum il-18 and rs187238 single nucleotide polymorphism are associated with high-density lipoprotein changes in covid-19 outpatients. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110645
BibTeX
@article{Viana2023,
author = {Viana, Glautemberg de Almeida and da Costa, Mac Dionys Rodrigues and da Silva, Mateus Edson and Duque, Bruna Ribeiro and de Siqueira, Erlânia Alves and Martins, Alice Maria Costa and Alves, Renata de Sousa and de Menezes, Ramon Róseo Paula Pessoa Bezerra and de Queiroz, Maria Goretti Rodrigues and Sampaio, Tiago Lima},
title = {Serum il-18 and rs187238 single nucleotide polymorphism are associated with high-density lipoprotein changes in covid-19 outpatients},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110645}
}
EUVIMED